Sun Pharma’s Dilip Shanghvi is known for his deep interest in research. His careful planning has helped the company build a portfolio of specialty products. Together they exceed a billion dollars in global sales. Now Shanghvi’s focus in on the lucrative weight-loss drugs that are sweeping across the world. Results from an early clinical trial on a new drug candidate has shown encouraging results, and Sun Pharma says it will take up further research. But medical experts say it will take a few years to know if Sun can make it to the finishing line. Besides, the competitive landscape is changing rapidly.
What an Indian pharma giant’s new drug find can gain the world’s obesity fight Selling weight-loss drugs is an opportunity no pharma company wants to miss. Now a leading drug maker from India joins this bandwagon. Decoding the deceit on 47 million fake Indian CVs While NEET exams expose the cheating problem, lying in résumé is a bigger issue. In a workforce of 470 million, over 10% of Indian CVs contain discrepancies, says data. The stage is set
2 mins read, Last Updated:
Gift A Story
Share member-only stories with your friends or family and help them read it for free.
Gifting Limit Reached!
Hey , no more stories left for you to gift.
No worries! You will get a limit of 15 stories next month to share with your friends and family.
Refer & Earn
Get Unlimited Access to The Economic Times
